Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)

Table 4 Treatment during follow-up

	PF-ILD (n = 14,413)
	Patients with ≥ 1, n (%)	Median annual, n (IQR)^a
Drug consumption
Glucocorticoids (IV or oral)	9871 (68.5)	7.3 (2.2–11.0)
Mycophenolate mofetil or mycophenolic acid	1007 (7.0)	5.0 (2.0–8.1)
Azathioprine	960 (6.7)	3.0 (1.0–5.9)
Methotrexate	461 (3.2)	1.9 (0.6–5.0)
Rituximab	355 (2.5)	0.9 (0.5–1.6)
Cyclophosphamide	67 (0.5)	1.5 (0.6–3.0)
Anti-TNFα	239 (1.7)	5.4 (1.6–9.0)
Tocilizumab	27 (0.2)	1.8 (0.6–5.3)
Antifibrotics	229 (1.6)	3.4 (1.5–7.6)
Other treatment
Supplemental oxygen use	6020 (41.8)	9.2 (4.2–13.0)
Lung transplantation	126 (0.9)	0.2 (0.2–0.5)
Palliative care	3229 (22.4)	4.4 (0.8–17.2)
Haematopoietic stem cell transplantation	60 (0.4)	0.4 (0.2–0.8)

End of follow-up was defined as the earliest of patient death, end of study period (31 December 2017) or last available record (hospitalisation, consultation or healthcare reimbursement) in the data source. Patients with a data gap persisting beyond 12 months are considered to have their follow-up ceased at their last record
IQR interquartile range, IV intravenous, PF-ILD progressive fibrosing interstitial lung disease, TNF tumour necrosis factor
^aMedian annual value for those with ≥ 1 claim during the study period

ISSN: 1465-993X